This observation is interesting, since MCL is the histotype in which first generation mTOR inhibitors have been mostly clinically developed [3,4,8,37,38] with the European Medicines Agency (EMA) approval of temsirolimus for patients with relapsed/refractory disease [6,8]. This evidence concerns the gene MTOR and mantle cell lymphoma.